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Background: Proenkephalin (PENK) has been suggested as a novel biomarker for kidney 
function. We investigated the diagnostic and prognostic utility of plasma PENK in compari-
son with neutrophil gelatinase-associated lipocalin (NGAL) and estimated glomerular filtra-
tion rates (eGFR) in septic patients.
Methods: A total of 167 septic patients were enrolled: 99 with sepsis, 37 with septic shock, 
and 31 with suspected sepsis. PENK and NGAL concentrations were measured and GFR 
was estimated by using the isotope dilution mass spectrometry traceable-Modification of 
Diet in Renal Disease (MDRD) Study and three Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) equations: CKD-EPICr, CDK-EPICysC, and CKD-EPICr-CysC. The PENK, NGAL, 
and eGFR results were compared according to sepsis severity, presence or absence of acute 
kidney injury (AKI), and clinical outcomes.
Results: The PENK, NGAL, and eGFR results were significantly associated with sepsis se-
verity and differed significantly between patients with and without AKI only in the sepsis 
group (all P <0.05). PENK was superior to NGAL in predicting AKI (P =0.022) and renal 
replacement therapy (RRT) (P =0.0085). Regardless of the variable GFR category by the 
different eGFR equations, PENK showed constant and significant associations with all eGFR 
equations. Unlike NGAL, PENK was not influenced by inflammation and predicted the 30-
day mortality.
Conclusions: PENK is a highly sensitive and objective biomarker of AKI and RRT and is 
useful for prognosis prediction in septic patients. With its diagnostic robustness and pre-
dictive power for survival, PENK constitutes a promising biomarker in critical care settings 
including sepsis.
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INTRODUCTION
Sepsis is defined as life-threatening organ dysfunction caused 
by a dysregulated host response to infection. Even a modest de-
gree of organ dysfunction may lead to the further deterioration 
of septic patients and an overall mortality of approximately 10%; 
thus, early recognition merits a prompt and appropriate inter-
vention [1]. Acute kidney injury (AKI) is common in critically ill 
patients and is a potentially life-threatening factor associated 
with significant morbidity and mortality [2, 3]. Sepsis is the most 
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common precipitating factor in the development of AKI, and sep-
sis-associated AKI (SA-AKI) is often more acute and severe com-
pared with AKI without sepsis, posing significant clinical chal-
lenges [4, 5].
A decrease in urine output and an increase in serum creati-
nine (Cr) have been used as surrogate markers for decreased 
glomerular filtration rate (GFR), which defines AKI [6]. However, 
because of the limitations of these classical parameters in as-
sessing acute kidney attack or damage, new renal biomarkers 
have been explored. Neutrophil gelatinase-associated lipocalin 
(NGAL) has been identified as a good predictor of AKI as well as 
an efficient test for predicting clinical outcome in critically ill pa-
tients [7, 8].
Several equations, such as the Isotope Dilution Mass Spec-
trometry (IDMS) Traceable-Modification of Diet in Renal Disease 
(MDRD) Study equation [9] and the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) equations using serum Cr, 
serum cystatin C (CysC), or both with demographic variables, 
have been used to estimate GFR [10, 11]. However, these equa-
tions for estimated GFR (eGFR) were developed for stable pa-
tients with chronic renal insufficiency and are not valid for criti-
cally ill patients [6, 12].
Enkephalins, encoded by the proenkephalin gene (PENK) on 
chromosome 8, are endogenous opioids involved in various phys-
iological processes and influence kidney function. Proenkepha-
lin (PENK; amino acids 119–159 of proenkephalin A), a stable 
surrogate marker for endogenous enkephalins, has been sug-
gested as a novel biomarker for AKI in perioperative and critical 
settings [13-15]. In this study, we investigated the clinical utility 
of PENK in comparison with NGAL in terms of AKI detection 
and prognosis prediction in septic patients. In addition, we com-
pared the levels of these two kidney biomarkers using four dif-
ferent eGFR equations (MDRD Study and three CKD-EPI equa-
tions) to explore how the equations vary across AKI and sepsis 
severity. This comparison highlights the necessity or stability of 
biomarkers in contrast to the unreliability of eGFR in critically ill 
patients.
METHODS
1. Study population
A total of 374 patients were under clinical suspicion of sepsis 
from December 2014 to June 2015; of these, 248 patients were 
diagnosed as having sepsis according to the diagnostic criteria 
of Surviving Sepsis Campaign 2012 [16]. Except for 81 patients 
without available samples, a total of 167 patients were enrolled 
in this study. Because the definition of sepsis and septic shock 
was revised in early 2016, the 167 enrolled patients were re-cat-
egorized according to the new definition [1]; 99 patients (59.2%) 
were diagnosed as having sepsis, 37 patients (22.2%) as hav-
ing septic shock, and 31 patients (18.6%), who could not be in-
cluded in the sepsis group according to the new definition, were 
arbitrarily grouped as suspected sepsis. This sample size was 
thought to have approximately 90% power to detect a difference 
in independent variables between the three sepsis grade groups 
with a 0.05 two-sided significant level. The patients’ medical re-
cords were reviewed for clinical and demographic data and their 
basic characteristics are presented in Table 1.
Presence of AKI was defined by using the Kidney Disease Im-
proving Global Outcomes (KDIGO) diagnostic criteria [17]. PENK, 
NGAL, serum Cr, and CysC concentrations were measured at 
the time of patient enrollment; the serum Cr delta value was as-
sessed on the basis of the concentrations 48 hr post enrollment 
for AKI diagnosis.
This study was performed in accordance with the Declaration 
of Helsinki, and the study protocol was reviewed and approved 
as exempt by the Institution Review Board (KUH1200051) of 
Konkuk University Medical Center, Seoul, Korea. The medical 
records were reviewed without any identifiable information, and 
this study did not require additional blood sampling or interven-
tion. The biomarkers were measured by using remnant blood 
samples that would have been discarded following routine use.
For each patient, available EDTA plasma and serum samples 
were collected on the same day as sepsis diagnosis, divided into 
small aliquots to avoid repeated freezing and thawing, and im-
mediately stored at -70°C until use. Frozen samples were thawed 
at room temperature and gently mixed just prior to biomarker 
measurement.
2. Measurement of PENK and NGAL
1) PENK assay
Plasma PENK was measured by using the sphingotest penKid 
assay (Sphingotec GmbH, Hennigsdorf, Germany), an immuno-
assay with monoclonal antibodies specific to the PENK peptide 
(amino acids 119–159 of PENK A). Standards (PENK peptide) 
and samples (100 µL) were incubated in tubes with the detec-
tor antibody (150 µL), the tubes were washed, and bound che-
miluminescence was detected with a LB952T/16 luminometer 
(Berthold, Bad Wildbad, Germany). The lower limit of detection 
was 5.5 pmol/L, the measurement range was 6.4–2,000.0 pmol/
L, and the mean within-laboratory imprecision was <9.5% dur-
ing the study period. The 99th percentile of the normal distribu-
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tion was 80 pmol/L, as recently described in the Malmö Diet and 
Cancer Study (n=4,643) [18], and was considered as a refer-
ence limit.
2) NGAL assay
Plasma NGAL was measured by using the Triage NGAL Assay 
(Alere, Inc., San Diego, CA, USA), according to the manufactur-
er’s instructions. Briefly, several drops of EDTA plasma sample 
were added to the sample port on the device; the sample then 
reacts with fluorescent antibody conjugates and the complexes 
are captured on a discrete zone specific for NGAL. The device 
displays the concentration of plasma NGAL approximately 15 
min later with a measurable range of 15–1,300 ng/mL. The 
mean within-laboratory imprecision was 2.8% during the study 
period. Medical decision point of plasma NGAL was set at 150 
ng/mL [7].
3. Estimation of GFR
Serum Cr was measured by using the Toshiba 200-FR analyzer 
(Toshiba Medical Systems, Tokyo, Japan) with the Roche cali-
brator and reagent (Roche Diagnostics, Indianapolis, IN, USA), 
which is traceable with the IDMS reference method. The dyna-
mic measuring range was 0.2–25 mg/dL, and the mean within-
laboratory imprecision was 1.35% during the study period. CysC 
was determined with the Roche Cobas 8000 modular system 
using Roche Tina-quant Cystatin C Gen 2, a particle enhanced 
immunonephelometric assay. The measurement range was 0.4–
8.0 mg/L, and the mean within-laboratory imprecision was 2.7% 
during the study period. eGFRs were calculated by using the 
MDRD Study equation and CKD-EPI equations using Cr, CysC, 
or Cr-CysC as variables with demographic variables [9-11]. To 
assess eGFR, rather than using arbitrary categories, we adopted 
six eGFR categories according to the KDIGO guidelines: ≥90 
mL/min/1.73 m2; 60–89 mL/min/ 1.73 m2; 45–59 mL/min/1.73 
m2; 30–44 mL/min/1.73 m2; 15–29 mL/min/1.73 m2; <15 mL/
min/1.73 m2 [19]. GFR ≥60 mL/min/1.73 m2 was considered 
normal.
4. Statistical analysis
Data were checked for normal distribution by using the Shapiro-
Wilk test and expressed as median and interquartile range or 
number and percentage. Groups were compared by using the 
Mann-Whitney U test or the Kruskal-Wallis test with post-hoc 
multiple comparisons. ROC curves and the area under the curves 
(AUC) were used to illustrate various cut-off levels with their sen-
sitivity and specificity. AUCs were reported with a 95% confidence 
interval (CI) and assessed as follows: 0.5–0.6, fail; 0.6–0.7, poor; 
0.7–0.8, fair; 0.8–0.9, good; 0.9–1.0, excellent [20]. Nested lo-
gistic regression models or ROC curves were used to compare 
variables for the prediction of AKI or renal replacement therapy 
(RRT). Agreement between the categorized groups was assessed 
by using the inter-rater agreement statistic (Kappa value): 0, ab-
Table 1. Characteristics of the study population and comparison between PENK, NGAL, and eGFRs according to sepsis severity
All patients 
(n=167)
Suspected sepsis 
(n=31)
Sepsis 
(n=99)
Septic shock 
(n=37)
P*
Age (yr), median [IQR] 70 [57–77] 67 [55–74] 70 [56–78] 72 [63–78] 0.3847
Male, n (%) 99 (59.3) 17 (54.8) 64 (64.6) 18 (48.6) 0.2053
Hospital stay (day), median [IQR] 14 [7–33.5] 21 [8–30] 14 [7–30] 7 [1–15] 0.0003
30-day mortality, n (%) 30 (18.0) 1 (3.2) 11 (11.1) 18 (48.6) <0.0001
AKI by KDIGO criteria, n (%) 41 (24.6) 4 (12.9) 19 (19.2) 18 (48.6) 0.0005
RRT, n (%) 24 (14.7) 0 (0.0) 18 (18.1) 6 (16.2) 0.0393
PENK (pmol/L), median [IQR] 89.6 [54.2–199.7] 52.1 [34.8–78.6] 94.8 [55.0–217.8] 158.0 [99.5–309.3] <0.000001
NGAL (ng/mL), median [IQR] 468 [219.3–945.5] 240.0 [121.3–510.0] 468.0 [225.0–976.3] 670.0 [342.3–1,300] 0.013
eGFR MDRD Study (mL/min/1.73 m2), median [IQR] 51.8 [23.3–88.8] 107.7 [86.0–138.2] 56.1 [29.8–96.5] 29.7 [19.8–58.0] <0.000001
eGFR CKD-EPICr (mL/min/1.73 m2), median [IQR] 70.2 [31.0–100.5] 100.4 [94.1–120.2] 63.4 [32.0–99.5] 31.2 [20.4–64.1] <0.000001
eGFR CKD-EPICysC (mL/min/1.73 m2), median [IQR] 53.2 [22.3–80.2] 72.9 [59.7–99.6] 42.2 [20.7–75.3] 28.0 [19.2–66.0] 0.000003
eGFR CKD-EPICr-CysC (mL/min/1.73 m2), median [IQR] 59.5 [27.5–90.4] 90.8 [76.1–109.6] 53.8 [24.6–86.9] 29.7 [19.9–51.7] <0.000001
Data are expressed as median [interquartile range] or number (percentage). 
*Kruskal-Wallis test.
Abbreviations: IQR, interquartile range; AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global Outcomes; RRT, renal replacement therapy; PENK, 
proenkephalin; NGAL, neutrophil gelatinase-associated lipocalin; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; 
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; CysC, cystatin C.
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sence of agreement; 0.1–0.2, none to slight; 0.21–0.40, fair; 0.41–
0.60, moderate; 0.61–0.80, substantial; 0.81–1.00, almost per-
fect agreement [21]. Kaplan-Meier survival curves were used to 
analyze the prognostic value of biomarkers and eGFRs, and 30-
day mortality was compared between favorable and unfavorable 
groups using the hazard ratio (HR, with 95% CI). SPSS software 
(version 22.0, SPSS Inc., Chicago, IL, USA) and MedCalc Soft-
ware (version 15.8, MedCalc Software, Mariakerke, Belgium) 
were used for statistical analyses. P values<0.05 were consid-
ered statistically significant.
RESULTS
Table 1 shows the comparison of PENK, NGAL, and eGFRs ac-
cording to sepsis severity. PENK and NGAL concentrations dif-
fered significantly according to sepsis severity (P <0.0001 and 
P =0.013, respectively). eGFRs based on the MDRD Study and 
three CKD-EPI equations decreased significantly according to 
sepsis severity (all P <0.0001).
AKI occurred in 12.9% (4/31) of patients with suspected-sep-
sis, 19.2% (19/99) of patients with sepsis, and 48.6% (18/37) 
of patients with septic shock (Table 2). The PENK and NGAL 
biomarkers and four eGFR equations differed significantly be-
tween patients with and without AKI at the stage of sepsis. Of 
note, in the sepsis stage, PENK concentration did not increase 
without AKI, while NGAL concentration increased substantially 
compared with the clinical cut-off value even without AKI (81.3 
pmol/L vs 361.5 ng/mL). Of the eGFR equations, only CKD-EPICr 
and CKD-EPICr-CysC indicated normal kidney function (GFR≥60 
mL/min/1.73 m2) in septic patients without AKI.
ROC curves were compared for AKI diagnosis in all 167 pa-
tients (Fig. 1). PENK (AUC, 0.725) and the four eGFR equations 
(AUC, 0.757, 0.761, 0.712, and 0.743, respectively) showed 
fair discriminatory ability, but NGAL demonstrated poor discrimi-
natory ability (AUC, 0.675). However, PENK, NGAL, and the 
four eGFR equations were all comparable, showing no statistical 
difference. A more refined analysis based on nested logistic re-
gression models showed that PENK was superior to NGAL (P = 
0.022), but inferior to the eGFR equations based on MDRD, Cr, 
and Cr-CysC (P <0.05). PENK exhibited no statistical superiority 
over eGFR based on CysC (P =0.473). NGAL was inferior to all 
eGFR equations (all P <0.05). The optimal cut-off value for AKI 
diagnosis was 154.5 pmol/L for PENK and 493 ng/mL for NGAL 
and ranged from 28.3 to 36.4 mL/min/1.73 m2 for the eGFR equa-
tions. With regard to RRT, both PENK and NGAL concentrations 
were significantly higher in patients with RRT than in patients 
without RRT (PENK, 421.9 vs 82.5 pmol/L, P <0.0001; NGAL, 
1,270.0 vs 375.0 ng/mL, P =0.0001). Based on ROC curve anal-
ysis, PENK showed good performance and NGAL showed fair 
performance to predict RRT (AUC, 0.872 vs 0.741, P =0.0085).
The distribution of GFR categories varied across each eGFR 
equation (Fig. 2). The proportion of reduced GFR (<60 mL/min/ 
1.73 m2) was the highest based on the CKD-EPICysC equation and 
the lowest based on the CKD-EPICr equation, showing a signifi-
cant difference (58.7% vs 44.9%, P <0.0001, Chi-square test). 
Of note, each pair of eGFR equations showed minimal to weak 
Table 2. Comparison of PENK, NGAL, and eGFR equations according to the presence or absence of AKI in each stage of sepsis
Suspected sepsis (n=31) Sepsis (n=99) Septic shock (n=37)
AKI (n=4) No AKI (n=27) P* AKI (n=19) No AKI (n=80) P* AKI (n=18) No AKI (n=19) P*
PENK (pmol/L) 66.9 
(50.7–84.6)
52.1 
(33.7–73.4)
0.3458 211.5 
(137.2–267.0)
81.3 
(53.5–160.5)
0.0034 199.7 
(101.7–304.3)
117.6 
(80.6–209.6)
0.2128 
NGAL (ng/mL) 336.0 
(125.5–558.5)
240 
(104.5–491.0)
0.7017 767.0
(386.8–1,300.0)
361.5 
(210.5–889.0)
0.0159 803 
(506.0–1,300)
471 
(270.3–931.5)
0.0857
MDRD Study (mL/min/1.73 m2) 82.6 
(66.8–123.7)
92.2 
(71.9–112.2)
0.5557 17.8 
(8.1–33.7)
51.9 
(30.2–89.2)
0.0001 23.0 
(16.9–29.7)
23.8 
(17.2–67.5)
0.2875
CKD–EPICr (mL/min/1.73 m2) 92.8 
(85.9–106.3)
100.5 
(95.0–120.7)
0.1573 21.9 
(10.5–46.5)
71.3 
(41.5–102.0)
0.0001 25.7 
(19.9–43.6)
29.5 
(17.9–83.2)
0.5038
CKD–EPICysC (mL/min/1.73 m2) 65.8 
(59.7–80.4)
80.8 
(60.0–106.2)
0.4437 17.0 
(10.8–36.3)
53.4 
(29.1–78.0)
0.0005 25.7 
(19.9–43.6)
29.5 
(17.9–83.2)
0.5038
CKD–EPICr–CysC (mL/min/1.73 m2) 78.8 
(72.3–93.7)
91.8 
(76.3–115.2)
0.3165 16.9 
(10.5–40.2)
62.9 
(31.2–90.4)
0.0002 29.1 
(21.7–34.8)
38.7 
(19.8–76.6)
0.2740
Data are expressed as median (interquartile range).
*Mann–Whitney U test.
Abbreviations: see Table 1.
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agreement to define reduced GFR.
The distribution of PENK and NGAL concentrations differed 
significantly according to GFR category (all P <0.0001) (Fig. 3). 
Both PENK and NGAL concentrations increased significantly ac-
cording to GFR category based on the MDRD Study and CKD-
EPI equations (P <0.0001). In normal GFR (≥60 mL/min/1.73 
m2) categories, PENK concentration was below the 154.5 pmol/L 
cut-off obtained by ROC curve analysis and was also lower than 
or similar to the 99th percentile of the normal range (80 pmol/L). 
NGAL concentration was also below the 493 ng/mL cut-off ob-
tained by ROC curve analysis; however, it was higher than the 
literature- and manufacturer-recommended 150 ng/mL cut-off.
In terms of 30-day mortality, except for NGAL, PENK concen-
tration and eGFRs showed significant differences between sur-
vivors and non-survivors based on all four equations (all P <0.005) 
(Table 3). Based on survival analysis using two different cut-offs 
(optimal ROC curve analysis cut-off and literature- and/or man-
ufacturer-recommended cut-off), PENK and the eGFR equations 
all showed significant differences between the two groups (fa-
vorable vs unfavorable). However, no significant difference was 
observed for NGAL, regardless of cut-off. PENK showed the high-
est HR with the 80 pmol/L cut-off value (HR=7.9, P <0.0001).
DISCUSSION
In this study, PENK concentration, NGAL concentration, and 
eGFRs all showed significant differences according to sepsis se-
verity (Table 1). Both PENK and NGAL concentrations increased 
significantly, while all eGFRs decreased significantly according 
to sepsis severity. Based on ROC curve analysis, PENK and the 
four eGFR equations showed fair discriminatory ability, while 
NGAL showed poor performance for AKI diagnosis (Fig. 1). In 
the nested logistic regression models, PENK was superior to 
NGAL (P =0.022), but inferior to the eGFR equations based on 
MDRD Study, Cr, and Cr-CysC (P <0.05). PENK did not display 
statistical superiority over eGFR based on CysC (P =0.473). NGAL 
Cut-off AUC (95% CI) Sensitivity (%) (95% CI) Specificity (%) (95% CI)
PENK 154.5 pmol/L 0.725 (0.651–0.791) 65.9 (49.4–79.9) 79.4 (71.2–86.1)
NGAL 493 ng/mL 0.675 (0.599–0.746) 73.2 (57.1–85.8) 60.3 (51.2–68.9)
MDRD Study 36.4 mL/min/1.73 m2 0.757 (0.685–0.821) 75.6 (59.7–87.6) 73.6 (65.0–81.1)
CKD-EPICr 34.5 mL/min/1.73 m2 0.761 (0.689–0.823) 73.2 (57.1–85.8) 75.4 (66.9–82.6)
CKD-EPICysC 28.3 mL/min/1.73 m2 0.712 (0.637–0.779) 63.4 (46.9–77.9) 77.8 (69.5–84.7)
CKD-EPICr-CysC 34.8 mL/min/1.73 m2 0.743 (0.669–0.807) 68.3 (51.9–81.9) 75.4 (66.9–82.6)
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Fig. 1. Comparison of the receiver operating characteristics curves for the diagnosis of AKI in septic patients. PENK and the four eGFR equa-
tions showed fair discriminatory ability, but NGAL showed poor discriminatory ability. However, PENK, NGAL, and the four eGFR equations 
were all comparable and showed no statistical difference. 
Abbreviations: see Table 1.
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was inferior to all eGFR equations (all P <0.05). Of note, both 
PENK and NGAL concentrations were significantly different be-
tween the two groups of RRT, and PENK predicted RRT better 
than NGAL (P =0.0085). These results indicate that the perfor-
mance of tested AKI biomarkers is not distinctly better than that 
of eGFR; however, PENK might predict the need for RRT more 
accurately.
According to our data, each pair of the four eGFR equations 
showed only minimal to weak agreement for defining reduced 
GFR (eGFR<60 mL/min/1.73 m2) (Fig. 2). The proportion of re-
duced GFR was the highest based on the CKD-EPICysC equation 
and the lowest based on the CKD-EPICr equation (58.7% vs 44.9%, 
P <0.0001). This finding implies that the clinical decision regard-
ing reduced GFR can be greatly affected by the eGFR equation 
used [22]. This is in line with the current recommendation not 
to use formulas to estimate GFR in critically ill patients [6]. Al-
though it is recommended to estimate GFR by the calculated Cr 
clearance using the UV/P (mL/min) formula in these patients, 
this technique requires the collection of at least one hour’s worth 
of urine, which could constitute an obstacle from a practical view-
point [6, 12]. With the current serum Cr-based AKI definition, 
AKI mortality and morbidity remain high and the detection of 
suboptimal and/or early kidney injury is not optimal; thus, AKI 
diagnosis is shifting from clinical to molecular diagnosis [23]. In 
this regard, the availability of stable, surrogate renal biomarkers 
would be beneficial; PENK could be a promising option instead 
of using equations or formulas.
Another noticeable finding was that PENK, NGAL, and the 
four eGFR equations showed significant differences between 
patients with and without AKI only in the sepsis stage (Table 2). 
Moreover, in the sepsis stage, PENK concentration did not in-
crease without AKI, while NGAL concentration increased sub-
stantially above its clinical cut-off value even without AKI (81.3 
pmol/L for PENK vs 361.5 ng/mL for NGAL). Of the four eGFR 
equations, only CKD-EPICr and CKD-EPICr-CysC indicated normal 
kidney function (GFR≥60 mL/min/1.73 m2) in septic patients 
without AKI.
The pathophysiology driving SA-AKI is not completely under-
stood and is distinct from other AKIs [5, 24, 25]. SA-AKI may 
have numerous drivers, including ischemic-reperfusion injury to 
the glomerulus, inflammation of specific parts of the nephron, 
hypoxic and/or oxidant stress, cytokine- and chemokine driven 
tubular injury, and tubular and mesenchymal apoptosis [5, 26]. 
Moreover, septic shock is a subset of sepsis characterized by a 
state of acute circulatory failure associated with infection. Our 
data shows that both renal biomarkers increased and the four 
eGFR equations decreased in the septic shock stage, even in 
patients without AKI (Table 1 and Table 2). In addition to its role 
as a renal biomarker, PENK has also been reported to be an in-
dependent predictor of heart failure [27, 28]. Taken together, 
increased PENK concentration in the septic shock stage can be 
explained by both renal and cardiac dysfunction. The observa-
tion of decreased eGFR in septic shock without AKI also sup-
ports the recent recommendation not to use eGFR equations for 
these critically ill patients [6]. In this study, AKI was diagnosed 
based on serum Cr change according to the KDIGO criteria [17]. 
However, the increase in serum Cr occurs relatively late, 24–48 
hr after kidney injury. In view of this inherent limitation of the se-
rum Cr-based definition of AKI, subclinical AKI has been sug-
gested by the Acute Dialysis Quality Initiative (ADQI)-10 consen-
sus work group [29]. High PENK concentrations in the septic 
shock stage may suggest the presence of subclinical AKI, which 
Fig. 2. Distribution and agreement of glomerular filtration rate (GFR) 
categories by each eGFR equation. The distribution of GFR catego-
ries varied across each eGFR equation. The proportion of reduced 
GFR (<60 mL/min/1.73 m2) was the highest based on the CKD-
EPICysC equation and the lowest based on the CKD-EPICr equation 
(58.7% vs 44.9%, P <0.0001, Chi-square test). All eGFR equations 
showed minimal to weak agreement with each other (Kappa value, 
0.310–0.541). Abbreviations: see Table 1.
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(0.324–0.497)
0.383 
(0.292–0.473)
0.508 
(0.418–0.598)
CKD-EPICr 0.310 
(0.223–0.397)
0.509 
(0.421–0.597) 
CKD-EPICysC 0.541 
(0.453–0.629)
CKD-EPICr-CysC
Data are expressed as Kappa value (95% confidence interval).
100
90
80
70
60
50
40
30
20
10
0
 MDRD Study CKD-EPICr CKD-EPICysC CKD-EPICr-CysC
Pr
op
or
tio
n 
(%
)
55.0%
45.0%
44.9%
55.1%
58.7%
41.3%
52.3%
49.7%
<15
15–29
30–44
45–59
60–89
≥90
(Unit: 
mL/min/1.73 m2)
Kim H, et al.
PENK, NGAL, and eGFR in sepsis
394  www.annlabmed.org https://doi.org/10.3343/alm.2017.37.5.388
Fig. 3. Comparison of PENK and NGAL concentrations according to GFR category. The distribution of PENK and NGAL concentrations dif-
fered significantly according to eGFR by each eGFR equation (all P <0.000001, Kruskal-Wallis test). (A) The median PENK concentration 
was below the 154.5 pmol/L cut-off obtained by the ROC curve analysis and was also lower than or similar to the 99th percentile of the nor-
mal range (80 pmol/L) in the normal GFR categories (≥60 mL/min/1.73 m2). (B) The median concentration of NGAL was below the 493 
ng/mL cut-off that was obtained by the ROC curve analysis; however, it was higher than the literature- and manufacturer-recommended 
150 ng/mL cut-off in the normal GFR categories. Data are expressed as median (interquartile range). Abbreviations: see Table 1.
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cannot be detected by the current definition.
PENK and NGAL concentrations increased significantly as GFR 
reduced according to the GFR categories (Fig. 3). Of note, re-
gardless of the eGFR equation used, PENK concentration was 
constantly lower than the 154.5 pmol/L cut-off in normal GFR 
(≥60 mL/min/1.73 m2) categories and it was also lower than 
the 99th percentile of the normal range (80 pmol/L). However, 
NGAL concentrations were higher than the literature- and man-
ufacturer-recommended 150 ng/mL cut-off, although they were 
below the 493 ng/mL ROC curve analysis cut-off. These find-
ings imply that PENK may reflect GFR better than NGAL and 
may not be influenced by inflammation. Otto et al [30] reported 
that the function of circulating plasma NGAL is not restricted 
solely to the detection of AKI; it might be involved in immune re-
sponse during inflammation. PENK would be a reliable and ob-
jective alternative to eGFR equations for defining reduced GFR 
and the presence of AKI in septic patients.
Marino et al [14] reported that admission PENK and NGAL 
concentrations were increased in patients who died within seven 
day of admission, while procalcitonin and Cr clearance were not. 
In the present study, PENK concentration and eGFRs based on 
the four equations all showed significant differences between 
survivors and non-survivors (Table 3). We also observed signifi-
cant differences between the two groups (favorable vs unfavor-
able) in the survival analysis using two different cut-offs. How-
ever, no significant differences were observed for NGAL, regard-
less of the cut-off. Our data suggests that PENK is superior to 
NGAL in predicting clinical outcome in septic patients. More-
over, the highest HR was observed when the 80 pmol/L cut-off 
was applied for PENK. This finding supports the appropriate-
ness and clinical usefulness of this cut-off in septic conditions 
[18].
This study has several limitations. We focused on the com-
parison between PENK and NGAL concentrations with eGFR 
equations in terms of AKI diagnosis and prognosis prediction; 
thus, we did not investigate the distribution of these biomarkers 
in relation to the specific bacteriological identification. In addi-
tion, we did not compare PENK and NGAL with the other AKI 
biomarkers including interleukin 8 and kidney injury molecule-1. 
We could not collect follow-up samples for serial observation of 
these biomarkers in septic patients. This study was a cross-sec-
tional retrospective registry study; therefore, it was difficult to 
observe the temporary development of AKI in association with 
PENK and NGAL increase. Although we compared eGFRs ac-
cording to the MDRD Study and CKD-EPI equations, we did not 
measure the actual value of GFR; therefore, we could not deter-
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mine which eGFR value was the closest to true GFR. Lastly, we 
had no information regarding PENK dynamics between pre- and 
post-RRT; because of its low molecular weight (5 kDa), it might 
have been dialyzed. Thus, further studies are necessary to an-
swer these questions.
In conclusion, this is the first study to demonstrate the useful-
ness of PENK in comparison with NGAL and eGFR equations 
for the diagnosis of AKI and prediction of prognosis in septic pa-
tients. Regardless of the variability of GFR category by the differ-
ent eGFR equations, PENK showed constant and significant as-
sociations with all the eGFR equations. In contrast to NGAL, PENK 
was not influenced by inflammation and predicted clinical out-
come. With its diagnostic robustness and predictive power for 
survival, PENK constitutes a promising biomarker in critical care 
settings including sepsis.
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